Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH by Martin, et al.
Use of the direct oral anticoagulants in obese patients: guidance 
from the SSC of the ISTH
K. MARTIN*, J. BEYER-WESTENDORF†, B. L. DAVIDSON‡, M. V. HUISMAN§, P. M. 
SANDSET¶, and S. MOLL*
*Department of Medicine, Division of Hematology-Oncology, University of North Carolina, Chapel 
Hill, NC, USA †Thrombosis Research Unit, Center for Vascular Diseases, University Hospital, 
Technische Universität Dresden, Dresden, Germany ‡Division of Pulmonary and Critical Care 
Medicine, University of Washington School of Medicine, Seattle, WA, USA §Department of 
Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands 
¶Department of Hematology, Oslo University Hospital and University of Oslo, Oslo, Norway
 Introduction
Four direct-acting oral anticoagulants (DOACs) – the thrombin inhibitor dabigatran, and the 
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban –are approved in 
many countries for the treatment of venous thromboembolism (VTE), the prevention of VTE 
after hip and knee arthroplasty, and ischemic stroke prevention in patients with non-valvular 
atrial fibrillation (AF). Because of their fixed dosing – without the need for routine 
monitoring – and limited dietary interactions, they are used as a convenient anticoagulant 
alternative to vitamin K antagonists (VKAs). In the product labeling (package inserts) of the 
approved DOACs, none has a dose adjustment for high weight or body mass index (BMI) in 
obese categories. However, there is uncertainty about their efficacy and safety in the obese 
population, with ‘obese’ defined by the National Institutes of Health as a BMI between 30 
kg m−2 and 40 kg m−2, and ‘extreme obesity’ as a BMI of > 40 kg m−2. Although a recent 
publication has suggested recommendations for use of DOACs in the obese population [1], 
data from clinical outcomes studies and pharmacokinetic (PK)/pharmacodynamic (PD) 
studies regarding the efficacy and safety of DOACs in obese patients are limited. We 
reviewed the available data on the use of DOACs in obese patients through a PubMed search 
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of key terms, including each DOAC in combination with the terms ‘pharmacokinetic’, 
‘pharmacodynamic’, ‘drug level’, ‘VTE’, ‘VTE prophylaxis’, and ‘atrial fibrillation’. Data 
on obese patients in phase III clinical trials were pooled by anticoagulation indication to 
obtain risk ratios for DOACs versus VKAs. Guidance statements were then developed to 
provide practical guidance for clinicians regarding the use of DOACs in obese patients.
 Evidence on the efficacy of VTE treatment and stroke prevention in AF
No large randomized controlled trial has specifically investigated the efficacy and safety of 
DOACs in the obese population. However, phase III clinical trials that demonstrated the 
efficacy and safety of DOACs as compared with VKAs included a moderate number of 
obese patients, and most included a subgroup analysis of efficacy by weight [2–11]. The 
conclusions are limited, however, by inconsistencies across studies, as shown in Table 1: the 
absolute weight cut-offs vary, and BMI stratification is found in only some analyses. 
Moreover, published data on the absolute weight of patients and the number of patients at 
the far extreme of weight in the trials are limited; none of the phase III clinical trials 
reported the number of patients enrolled with a BMI of > 40 kg m−2 or their clinical 
outcomes.
The weight category and number of obese patients in the phase III trials for each DOAC are 
listed in Table 1. All trials except ARISTOTLE and ENGAGE had a weight-based analysis 
for efficacy. Thus, two of four AF trials did not have a subanalysis by weight, and one AF 
trial (RE-LY) that analyzed by weight reported only an outcome rate per year and a total 
number of obese patients, without a breakdown of the number of patients in each treatment 
group. The major phase III trials that reported weight-based analyses demonstrated that the 
DOACs appeared to be equivalent to VKAs in the prevention of recurrent VTE and stroke in 
the highest-weight category of each of the trials, with a calculated risk ratio (RR) and a 95% 
confidence interval (CI) that crosses 1 (Figs S1 and S2). Additionally, the direct-acting oral 
anti-FXa agents appeared to be non-inferior in efficacy in obese patients as compared with 
normal-weight patients, with an equivalent calculated RR (Fig. S3). Notably, this did not 
hold true for a pooled analysis by weight of the use of dabigatran in VTE patients [10], in 
which the risk of the primary efficacy outcome was significantly higher for patients 
weighing > 100 kg than for patient of normal weight (50–100 kg) taking dabigatran (Fig. S3; 
RR 2.04, 95% CI 1.2–3.5). In addition to primary trial publications, two abstracts have 
published weight-based analyses. The first analyzed the RE-LY trial by BMI subgroups 
categorized into an upper 10% (BMI of > 36 kg m−2), a middle 80% (BMI of 22.5 to ≤ 36 
kg m−2), and a bottom 10% (BMI of ≤ 22.5 kg m−2), and found that the 1-year stroke/
systemic embolism (S/SE) rate did not significantly differ in the highest BMI category 
among treatment groups of dabigatran 110 mg (1.2%, 95% CI 0.3–2.0), dabigatran 150 mg 
(0.9%, 95% CI 0.1–1.6), and warfarin (1.3%, 95% CI 0.4–2.3) [12]. Furthermore, the BMI 
category had comparable rates of S/SE to the middle BMI category, although both the 
middle and upper BMI categories tended to have higher rates of S/SE than the lowest BMI 
category [12]. The second abstract analyzed data from the EINSTEIN deep vein thrombosis 
(DVT) and pulmonary embolism (PE) studies divided into three weight categories of 50 kg, 
50–100 kg, and > 100 kg, and found no association between body weight and risk of 
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recurrent VTE, and similar rates of recurrent VTE by treatment group in the highest weight 
category of > 100 kg (2.3% receiving DOACs versus 2.0% receiving VKAs) [13].
 Evidence on the safety of VTE treatment and stroke prevention in AF
The evidence surrounding the safety of DOACs in obese patients is more limited. Only half 
of the major phase III trials (including only one of the AF trials) included a safety subgroup 
analysis by weight, namely AMPLIFY, Hokusai-VTE, EINSTEIN-DVT, EINSTEIN-PE, 
and ROCKET-AF [2,5,7–9]. As in the primary efficacy analysis, the weight divisions were 
inconsistent, with differences in absolute kilograms and BMI cut-offs. Furthermore, primary 
safety outcomes differed among trials: all but one reported the composite outcome of major 
bleeding and clinically relevant non-major bleeding as the primary outcome, whereas 
AMPLIFY reported only major bleeding (Table S2). Overall, the subgroup analyses by 
weight suggest that DOACs are safe in obese patients with calculated RRs with a 95% CI 
crossing 1 (Fig. S4). Notably, in one trial (AMPLIFY), the major bleeding rate for patients 
with a BMI of > 35 kg m−2 receiving apixaban was significantly lower than that for obese 
patients receiving a VKA (apixaban 0.6% versus VKA 3.5%, RR 0.16, 95% CI 0.04–0.70). 
Additionally, a published abstract of a subanalysis of the RE-LY data by BMI found that 1-
year major bleeding rates were comparable across treatment groups for patients in the upper 
10% of BMI (> 36 kg m−2), with major bleeding rates for dabigatran 110 mg, dabigatran 
150 mg and warfarin of 3% (95% CI 1.6–4.4), 4.4% (95% CI 2.7–6.1), and 3.7% (95% CI 
2.2–5.2), respectively [12].
 Evidence on the efficacy and safety of thromboprophylaxis following 
joint arthroplasty
Although large trials investigating the DOACs for thromboprophylaxis in orthopedic 
surgeries also included moderate numbers of obese patients, none of the initial publications 
included a subgroup analysis by weight. Subsequently, however, pooled analyses that 
include a subanalysis by weight have been published for each of the four DOACs. First, a 
pooled analysis of three phase III trials comparing dabigatran with enoxaparin 40 mg daily 
for prophylaxis in orthopedic surgeries (RE-MODEL, RE-NOVATE, and RE-NOVATE II) 
found similar rates of VTE (2.7% in patients receiving dabigatran versus 2.9% in patients 
receiving enoxaparin; odds ratio [OR] 0.92, 95% CI 0.5–1.7), major bleeding (1.3% in 
patients receiving dabigatran versus 1.1% in patients receiving enoxaparin; OR 1.25, 95% CI 
0.5–2.9) and a composite outcome of major plus clinically relevant non-major bleeding 
(CRNMB) (5.4% in patients receiving dabigatran versus 4.6% in patients receiving 
enoxaparin; OR 1.17, 95% CI 0.8–1.8) in the highest BMI category (> 30 kg m−2) [14]. 
Furthermore, the rates of efficacy and safety were similar in each treatment group across 
obesity subgroups of BMI 30–35 kg m−2, 35–40 kg m−2, and > 40 kg m−2 [14].
A pooled analysis of two apixaban studies, ADVANCE-2 and ADVANCE-3, comparing 2.5 
mg of apixaban to 40 mg daily of enoxaparin, also included an analysis by body weight and 
BMI, and found a similar primary VTE outcome rate between treatment groups in the 
highest BMI category (≥ 30 kg m−2) (1.0% in patients receiving apixaban versus 1.9% in 
patients receiving enoxaparin; RR 0.52, 95% CI 0.25–1.07), as well as similar rates of major 
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bleeding (0.5% in patients receiving apixaban versus 0.7% in patients receiving enoxaparin; 
absolute risk difference − 0.24, 95% CI − 0.79 to 0.30) and CRNMB (3.6% in patients 
receiving apixaban versus 4.9% in patients receiving enoxaparin; absolute risk difference 
1.34, 95% CI − 2.8 to 0.1) [15].
Similarly, a pooled analysis of four phase III studies (RECORD-1, RECORD-2, 
RECORD-3, and RECORD-4) of rivaroxaban for thromboprophylaxis following orthopedic 
surgeries demonstrated similar rates of symptomatic VTE and all-cause mortality in each 
treatment group for patients weighing > 90 kg (0.6% in patients receiving rivaroxaban versus 
1.3% in patients receiving enoxaparin; hazard ratio [HR] 0.49, 95% CI 0.2–1.1). In the 
safety analysis of the composite of major bleeding and CRNMB within the same highest 
weight subgroup, rivaroxaban was associated with an insignificant increase in bleeding as 
compared with enoxaparin (4.4% versus 2.7%; HR 1.6, 95% CI 1.1–2.4) [16].
 Evidence on efficacy and safety from PK/PD data
In the absence of randomized controlled trials, PK/PD studies supplement data by providing 
insights into the effects of body weight on plasma drug concentrations, expected drug 
exposure, and half-lives. The available PK/PD data for each DOAC are summarized below.
A subgroup analysis of dabigatran peak and trough concentrations within the RELY trial 
demonstrated an inverse relationship between trough concentration and weight, with dose-
normalized trough concentrations that were 21% lower for the high body weight group (> 
100 kg) than for the reference body weight group (50–100 kg) [17]. A multivariate analysis 
showed an inverse relationship between trough concentration and the probability of an 
ischemic event; however, weight was not found to be a significant covariate for stroke in 
logistic regression of events [17].
A study of the pharmacokinetics of apixaban in healthy volunteers at the extremes of body 
weight included a comparison of a high body weight group (weight of > 120 kg and BMI of 
≥ 30 kg m−2) and a reference group (weight of 65–85 kg), and found a 31% lower mean 
peak apixaban concentration (144 ng mL−1 [coefficient of variation (CV) of 28%] versus 
207 ng mL−1 [CV 24%]), a 24% higher volume of distribution (Vd) (75.6 L [standard 
deviation (SD) 28] versus 61.0 L [SD 22]) and a 23% lower drug exposure (area under the 
curve [AUC] of 1561 ng h mL−1 [CV 31%] versus 2024 ng h mL−1 [CV 24%]) in the high 
body weight group than in the reference body weight group[18]. The 20% lower apixaban 
exposure in the high body weight group resulted in a statistically significant inverse 
relationship between apixaban exposure and body weight (P < 0.001); however, the authors 
concluded that, because the effect was modest, there was no need to adjust the dose of 
apixaban in patients weighing > 120 kg. Additionally, the mean half-life of apixaban was 
found to be 8.8 h (SD 3.2) in the high body weight group as compared with 12.0 h (SD 5.4) 
in the reference weight group, but this was interpreted as unlikely to be clinically significant 
[18].
Although no studies examining the effects of body weight on the pharmacokinetics of 
edoxaban have been published to date, one study analyzed pooled data from 11 clinical 
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studies of edoxaban, and included body weight as a covariate [19]. The analysis included 
subjects with body weights ranging from 31 kg to 165 kg, with a mean of 81.8 kg. On the 
basis of the developed model, body weight significantly affected the non-renal clearance of 
edoxaban, with non-renal clearance decreasing with lower body weight [19].
Two studies have examined the effects of obesity on the pharmacokinetics of rivaroxaban. 
The first examined the pharmacokinetics of rivaroxaban at the extremes of body weight in a 
small study of healthy volunteers, and demonstrated similar peak plasma concentrations 
(149.0 ng mL−1 [CV 20.4%] versus 143.4 ng mL−1 [CV 26.5%]), AUCs (1155 μg h L−1 [CV 
15.6%] versus 1029 μg h L−1 [CV 20.1%]) and half-lives (7.30 h [CV 25.4%] versus 7.20 h 
[CV 42.1%]) for rivaroxaban in a group of subjects weighing > 120 kg and in a group of 
subjects weighing 70–80 kg, respectively, suggesting that obesity does not significantly 
affect the peak concentration, distribution or half-life of rivaroxaban [20]. The second study 
developed a PK model for rivaroxaban by using pooled data of patients with acute DVT 
from two phase II studies (EINSTEIN-DVT and ODIXa-DVT trials), and did not find 
maximum plasma drug levels to be significantly influenced by body weight [21]. Vd, 
however, directly correlated with body weight, with a decrease in Vd of 0.8% per kg below 
the median low body weight of 56 kg [21]. Therefore, on the basis of this model, higher-
weight individuals may have increased Vd levels, although the clinical significance of this is 
unknown.
 Discussion
As no randomized controlled trials of DOACs administered to large numbers of obese 
patients exist, decisions regarding the use of DOACs in this population must, instead, rely on 
the available evidence. Subgroup analyses of obese patients that were included in the large 
phase III DOAC trials suggest that DOACs are efficacious and safe in these patients. 
However, this conclusion must be tempered by the lack of available data on the extremes of 
weight and the numbers of patients in these extremes. PK/PD studies indicate that increasing 
body weight has a modest overall effect on PK parameters of the DOACs at the ranges 
tested, but suggest reduced drug exposure, lower peak concentrations and shorter half-lives 
of the drugs with higher body weights. The clinical implications of such changes are 
unknown, but they raise concerns about underdosing of DOACs in patients at the extremes 
of obesity. Checking DOAC-specific anticoagulant blood levels to attempt to assess 
anticoagulant effects in obese patients is problematic, for logistic and interpretative reasons. 
First, there are currently no defined therapeutic ranges for DOAC drug levels. Furthermore, 
the published levels show high interpatient variability among subjects for a given dose, and 
among populations with different indications for anticoagulation [22–25]. In addition to 
between-subject variability, there is high variability of dabigatran levels in the same patient; 
hence, one level may not be sufficient to reliably identify a patient with extreme values [23]. 
Currently, it is not known whether the other DOACs also have pronounced intraindividual 
variability. Therefore, although a DOAC-specific level may suggest that a patient is within 
an ‘on-therapy’ range, the interpretation of testing and its use in clinical management 
continue to be extremely challenging.
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The guidance statements are meant to provide practical guidance for clinicians regarding the 
use of DOACs in obese patients. ‘Recommend’ indicates a strong guidance statement based 
on existing literature, whereby the clinician should consider adopting the practice in most 
cases, whereas ‘suggest’ reflects a weak guidance statement due to limited existing literature 
whereby the clinician may adopt the guidance statement or use an alternative approach to 
manage patients. As for all cases, our statements may provide guidance but do not replace 
clinical judgement for the management of individual patients.
 Guidance statements
1. We recommend appropriate standard dosing of the DOACs in patients with a 
BMI less than or equal to 40 kg m−2 and weight less than or equal to 120 kg 
for VTE treatment, VTE prevention, and prevention of ischemic stroke and 
systemic arterial embolism in non-valvular AF.
2. We suggest that DOACs should not be used in patients with a BMI of > 40 kg 
m−2 or a weight of > 120 kg, because there are limited clinical data available 
for patients at the extreme of weight, and the available PK/PD evidence 
suggests that decreased drug exposures, reduced peak concentrations and 
shorter half-lives occur with increasing weight, which raises concerns about 
underdosing in the population at the extreme of weight.
3. If DOACs are used in a patient with a BMI of > 40 kg m−2 or a weight of > 
120 kg, we suggest checking a drug-specific peak and trough level (anti-FXa 
for apixaban, edoxaban, and rivaroxaban; ecarin time or dilute thrombin time 
with appropriate calibrators for dabigatran; or mass spectrometry drug level for 
any of the DOACs). If the level falls within the expected range, continuation of 
the DOAC seems reasonable. However, if the drug-specific level is found to be 
below the expected range (Table S1) [17,24,26–29], we suggest changing to a 
VKA rather than adjusting the dose of the DOAC.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Weight categories and number of obese patients in major phase III trials
Drug Trial Weight categories Number of obese patients (%)
Dabigatran RE-COVER I ≥ 100 kg 502/2539 (20)
BMI ≥ 35 306/2539 (12)
RE-COVER II > 100 kg 438/1280 (34.2)
BMI > 35 302/1280 (23.6)
RE-LY ≥ 100 kg 3099/18 113 (17.1)
RE-MEDY ≥ 100 kg 299/1430 (20.9)
RE-SONATE ≥ 100 kg 122/681 (17.9)
Rivaroxaban EINSTEIN DVT > 100 kg 245/1731 (14.2)
EINSTEIN PE > 100 kg 345/2419 (14.3)
EINSTEIN EXTENSION > 100 kg 85/602 (14.1)
ROCKET-AF > 90 kg 2035/7131 (28.5)
BMI > 35 972/7131 (13.6)
Apixaban AMPLIFY ≥ 100 kg 522/2691 (19.4)
BMI > 35 349/2691 (13.0)
ARISTOTLE None
Edoxaban ENGAGE AF TIMI 48 None
HOKUSAI VTE > 100 kg 611/4118 (14.8)
BMI, body mass index.
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